Another of PepGen’s trials has encountered resistance from the FDA, with the regulator now putting the company’s plans to ...

After its eye disease antibody flopped in an FDA-requested clinical trial in late November, Outlook Therapeutics is ...

Foghorn Therapeutics has finally given up on its only wholly-owned clinical-stage candidate after the troubled cancer drug ...

Edgewise Therapeutics’ lead candidate has been shown to reduce levels of a biomarker related to skeletal muscle damage in a ...

PureTech’s only internal drug program has slowed lung function decline in a phase 2 trial in idiopathic pulmonary fibrosis ...

Discover how the Inventus Connect eSIM solutions, designed specifically for provisioned devices in clinical trials, are ...

Pharming is paying $66.1 million to acquire Swedish biotech Abliva and its phase 2-stage med that the Dutch drugmaker ...

Gilead Sciences has raided Sanofi for its next chief medical officer, luring Dietmar Berger, M.D., Ph.D., away from the ...

Incyte is dropping a program for patients with myelofibrosis-related anemia after its investigational small molecule failed ...

The data include an interim look at the dose-escalation portion of a phase 2 trial assessing the adenosine A2A receptor ...

Emma Reeve, the chair of Editas’ board, is also resigning, to be replaced by Jessica Hopfield, Ph.D., the company explained ...

A phase 3 prostate cancer trial of Candel’s oncolytic virus has met its primary endpoint, sending the stock up more than 200% ...